BrightSpring Health Services, Inc. (BTSG) stock
Close on Oct 30, 2026Market cap $13.24BP/E 36.4Yield –
Earnings
BrightSpring Health Services's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.
Quarterly results
Revenue and earnings per share from each of BrightSpring Health Services's earnings releases, newest first
| Quarter | Reported | Revenue | YoY | EPS | Adj. EPS | Source |
|---|---|---|---|---|---|---|
| Q4 FY2026ended Dec 31, 2026 | Feb 26, 2027Expected | – | – | – | – | – |
| Q3 FY2026ended Sep 30, 2026 | Oct 30, 2026before the open | $4.21B | +26.4% | $0.46 | $0.54 | Release |
| Q2 FY2026ended Jun 30, 2026 | Jul 31, 2026before the open | $3.87B | +23.0% | $0.38 | $0.45 | Release |
| Q1 FY2026ended Mar 31, 2026 | May 1, 2026before the open | $3.61B | +25.6% | – | – | Release |
| Q4 FY2025ended Dec 31, 2025 | Feb 27, 2026before the open | $3.55B | +16.3% | $0.35 | $0.33 | Release |
| Q3 FY2025ended Sep 30, 2025 | Oct 28, 2025during market hours | $3.33B | +14.7% | $0.17 | $0.30 | Release |
| Q2 FY2025ended Jun 30, 2025 | Aug 1, 2025before the open | $3.15B | +15.3% | – | $0.22 | Release |
| Q1 FY2025ended Mar 31, 2025 | May 2, 2025before the open | $2.88B | +11.7% | $0.14 | $0.19 | Release |
| Q4 FY2024ended Dec 31, 2024 | Mar 6, 2025before the open | $3.05B | +28.5% | $0.08 | $0.22 | Release |
| Q3 FY2024ended Sep 30, 2024 | Nov 1, 2024before the open | $2.91B | – | -$0.04 | $0.11 | Release |
| Q2 FY2024ended Jun 30, 2024 | Aug 2, 2024before the open | $2.73B | – | $0.10 | $0.10 | Release |
| Q1 FY2024ended Mar 31, 2024 | May 2, 2024before the open | $2.58B | – | -$0.26 | $0.12 | Release |
| Q4 FY2023ended Dec 31, 2023 | Feb 29, 2024before the open | $2.38B | – | -$0.06 | – | Release |
Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.
Current guidance
BrightSpring Health Services's latest outlook for periods it has not reported yet, compared with what it said before
| Metric | Period | Guidance | Before | Change | Given |
|---|---|---|---|---|---|
| Provider Segment Revenue | FY2026 | $1.90B – $1.93B | $1.88B – $1.93B | Lowered | Jul 31, 2026 |
| Provider Segment Revenue growth | FY2026 | +29.7% – +31.4% | +14.1% – +17.9% | Raised | Jul 31, 2026 |
| Revenues | FY2026 | $15.90B – $16.13B | – | New | Oct 30, 2026 |
| Total Adjusted EBITDAnon-GAAP | FY2026 | $850.00M – $860.00M | – | New | Oct 30, 2026 |
| Total Adjusted EBITDAnon-GAAP | FY2026 | $820.00M – $845.00M | $795.00M – $825.00M | Raised | Jul 31, 2026 |
| Total Adjusted EBITDA growthnon-GAAP | FY2026 | +32.8% – +36.8% | +28.7% – +33.6% | Raised | Jul 31, 2026 |
Guidance vs results
The last range BrightSpring Health Services gave before each report, against the figure it then reported. Full years add up the four quarters.
| Period | Metric | Guidance | Actual | Result |
|---|---|---|---|---|
| FY2025 | Revenue | $12.40B – $12.70B | $12.91BΣ4Q | Above range |
| FY2025 | Revenue growth | +23.1% – +26.1% | +14.59%Σ4Q | Below range |
Guidance history
Every forecast BrightSpring Health Services put in an earnings release, newest first
| Given | Metric | Period | Guidance | Change |
|---|---|---|---|---|
| Oct 30, 2026 | Total Adjusted EBITDA | FY2026 | $850.00M – $860.00M | New |
| Oct 30, 2026 | Revenues | FY2026 | $15.90B – $16.13B | New |
| Jul 31, 2026 | Total Adjusted EBITDA | FY2026 | $820.00M – $845.00M | Raised |
| Jul 31, 2026 | Adjusted EBITDA in 2026 | FY2026 | $35.00M | Lowered |
| Jul 31, 2026 | Total Adjusted EBITDA growth | FY2026 | +32.8% – +36.8% | Raised |
| Jul 31, 2026 | Provider Segment Revenue | FY2026 | $1.90B – $1.93B | Lowered |
| Jul 31, 2026 | Provider Segment Revenue growth | FY2026 | +29.7% – +31.4% | Raised |
| Jul 31, 2026 | Revenues growth | FY2026 | +17% – +19.5% | Lowered |
| Jul 31, 2026 | Pharmacy Segment Revenue growth | FY2026 | +15.3% – +17.9% | Lowered |
| Jul 31, 2026 | Revenues | FY2026 | $15.10B – $15.43B | Raised |
| Jul 31, 2026 | Pharmacy Segment Revenue | FY2026 | $13.20B – $13.50B | Lowered |
| May 1, 2026 | Total Adjusted EBITDA growth | FY2026 | +28.7% – +33.6% | Raised |
| May 1, 2026 | Total Adjusted EBITDA | FY2026 | $795.00M – $825.00M | Raised |
| May 1, 2026 | Adjusted EBITDA | FY2026 | $30.00M | Lowered |
| May 1, 2026 | Provider Segment Revenue | FY2026 | $1.88B – $1.93B | Lowered |
| May 1, 2026 | Revenues growth | FY2026 | +14.1% – +17.9% | Lowered |
| May 1, 2026 | Pharmacy Segment Revenue growth | FY2026 | +12.3% – +16.2% | Lowered |
| May 1, 2026 | Provider Segment Revenue growth | FY2026 | +28% – +31.4% | Raised |
| May 1, 2026 | Revenues | FY2026 | $14.73B – $15.23B | Raised |
| May 1, 2026 | Pharmacy Segment Revenue | FY2026 | $12.85B – $13.30B | Lowered |
| Feb 27, 2026 | Total Adjusted EBITDA growth | FY2026 | +23.1% – +27.9% | New |
| Feb 27, 2026 | Total Adjusted EBITDA | FY2026 | $760.00M – $790.00M | New |
| Feb 27, 2026 | Adjusted EBITDA from Amedysis and LHC acquisition | FY2026 | $30.00M | Lowered |
| Feb 27, 2026 | Revenues growth | FY2026 | +11.9% – +16.2% | New |
| Feb 27, 2026 | Pharmacy Segment Revenue growth | FY2026 | +10.1% – +14.5% | Lowered |
| Feb 27, 2026 | Provider Segment Revenue growth | FY2026 | +26.3% – +29.7% | Raised |
| Feb 27, 2026 | Revenues | FY2026 | $14.45B – $15.00B | New |
| Feb 27, 2026 | Pharmacy Segment Revenue | FY2026 | $12.60B – $13.10B | Lowered |
| Feb 27, 2026 | Provider Segment Revenue | FY2026 | $1.85B – $1.90B | Lowered |
| Oct 28, 2025 | Adjusted EBITDA | FY2025 | $605.00M – $615.00M | Raised |
| Oct 28, 2025 | Revenues | FY2025 | $12.50B – $12.80B | Raised |
| Oct 20, 2025 | Adjusted EBITDA growth | FY2025 | +31.5% – +33.7% | New |
| Oct 20, 2025 | Adjusted EBITDA | FY2025 | $605.00M – $615.00M | New |
| Oct 20, 2025 | Revenues growth | FY2025 | +23.1% – +26.1% | New |
| Oct 20, 2025 | Pharmacy Segment Revenue growth | FY2025 | +25.1% – +27.9% | Raised |
| Oct 20, 2025 | Provider Segment Revenue growth | FY2025 | +10% – +13.8% | Lowered |
| Oct 20, 2025 | Revenues | FY2025 | $12.40B – $12.70B | New |
| Oct 20, 2025 | Pharmacy Segment Revenue | FY2025 | $10.95B – $11.20B | Lowered |
| Oct 20, 2025 | Provider Segment Revenue | FY2025 | $1.45B – $1.50B | Lowered |
| Aug 1, 2025 | Adjusted EBITDA growth | FY2025 | +28.2% – +31.5% | Raised |
| Aug 1, 2025 | Adjusted EBITDA | FY2025 | $590.00M – $605.00M | Raised |
| Aug 1, 2025 | Net Revenue growth | FY2025 | +21.1% – +25.1% | Raised |
| Aug 1, 2025 | Pharmacy Segment Revenue growth | FY2025 | +22.8% – +26.8% | Raised |
| Aug 1, 2025 | Provider Segment Revenue growth | FY2025 | +10% – +13.8% | Lowered |
| Aug 1, 2025 | Net Revenue | FY2025 | $12.20B – $12.60B | Raised |
| Aug 1, 2025 | Pharmacy Segment Revenue | FY2025 | $10.75B – $11.10B | Lowered |
| Aug 1, 2025 | Provider Segment Revenue | FY2025 | $1.45B – $1.50B | Lowered |
| May 2, 2025 | Adjusted EBITDA | FY2025 | $570.00M – $585.00M | Raised |
| May 2, 2025 | Net Revenue | FY2025 | $12.00B – $12.50B | Raised |
| Mar 6, 2025 | Adjusted EBITDA growth | FY2025 | +18.4% – +21.7% | New |
| Mar 6, 2025 | Adjusted EBITDA | FY2025 | $545.00M – $560.00M | New |
| Mar 6, 2025 | Net Revenue growth | FY2025 | +15.2% – +20.1% | New |
| Mar 6, 2025 | Pharmacy Segment Revenue growth | FY2025 | +15.9% – +21.1% | Raised |
| Mar 6, 2025 | Provider Segment Revenue growth | FY2025 | +10% – +13.8% | Lowered |
| Mar 6, 2025 | Net Revenue | FY2025 | $11.60B – $12.10B | New |
| Mar 6, 2025 | Pharmacy Segment Revenue | FY2025 | $10.15B – $10.60B | Lowered |
| Mar 6, 2025 | Provider Segment Revenue | FY2025 | $1.45B – $1.50B | Lowered |
| Nov 1, 2024 | Adjusted EBITDA growth | FY2024 | +14.2% – +15.2% | New |
| Nov 1, 2024 | Adjusted EBITDA | FY2024 | $580.00M – $585.00M | Raised |
| Nov 1, 2024 | Net revenue growth | FY2024 | +24.6% – +28% | New |
| Nov 1, 2024 | Pharmacy Segment Revenue growth | FY2024 | +30.3% – +34.2% | Raised |
| Nov 1, 2024 | Provider Segment Revenue growth | FY2024 | +8.5% – +10.7% | Lowered |
| Nov 1, 2024 | Net revenue | FY2024 | $11.00B – $11.30B | Raised |
| Nov 1, 2024 | Pharmacy Segment Revenue | FY2024 | $8.50B – $8.75B | Lowered |
| Nov 1, 2024 | Provider Segment Revenue | FY2024 | $2.50B – $2.55B | Lowered |
| Aug 2, 2024 | Adjusted EBITDA | FY2024 | $570.00M – $580.00M | Raised |
| Aug 2, 2024 | Net revenue | FY2024 | $10.45B – $10.90B | New |
| May 2, 2024 | Adjusted EBITDA | FY2024 | $555.00M – $570.00M | Raised |
| May 2, 2024 | Net revenue | FY2024 | $10.30B – $10.80B | Raised |
| Feb 29, 2024 | Adjusted EBITDA | FY2024 | $550.00M – $564.00M | New |
| Feb 29, 2024 | Net revenue | FY2024 | $9.35B – $9.50B | New |
| Feb 29, 2024 | Pharmacy Segment Revenue | FY2024 | $6.95B – $7.05B | Lowered |
| Feb 29, 2024 | Provider Segment Revenue | FY2024 | $2.40B – $2.45B | Lowered |
Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.
Press releases
Releases BrightSpring Health Services filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Update
- Results
- Update
- Update
- Results
- Results
- Results
- Results
- News
- News
- Results
- Results
- BrightSpring Health Services, Inc. Announces Promotion of Jennifer Phipps to Chief Financial OfficerUpdate